The recent AIIMS Bhubaneswar study evidencing ivermectin as a potential prophylactic against COVID-19 has generated more activity in the Indian press than typically observed with other studies centering on the U.S. Food and Drug Administration (FDA) approved antiparasitic medication. Although TrialSite reported recently that the national guidelines rejected the medication due to lack of evidence, perhaps this recent study may remind some in the national government not only of the potential but the fact that ivermectin is used across much of India at the state and local level in a multifaceted effort to fight COVID-19. Doctors from one of India’s premier medical schools declare that according to this study, the use of ivermectin has led to successful outcomes.
TrialSite News published the AIIMS study, which was published in preprint server medRxiv, highlighting that “Two-dose ivermectin prophylaxis at a dose of 300 μg/kg with a gap of 72 hours was associated with 73% reduction of COVID-19 infection among healthcare workers for the following one-month.” Rightly, the research team concluded that “Further research is required before its large-scale use.”
Again, for a summary of ...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).